Table 2.

Antibody concentration and neutralization titers achieved in plasma and vaginal fluidsa

AntibodyDose (mg/kg)Animal IDb12 concn in plasma at time of challenge (μg/ml)Neutralization titer in plasma at time of challenge (IC90)bb12 concn in vaginal fluid at time of challenge (μg/ml)
gp120 ELISAB2.1 ELISAgp120 ELISAB2.1 ELISA
b1225R3607108401:4003013.5
L4267256001:4002025
AV866959101:40018.627.9
P3116909401:40017.421.8
b125R0841802101:401.01.5
J5261752301:803.12.5
N8331703601:803.27.8
R2281702901:8022.237
b121T69312121:16NDND
AM4020201:16NDND
AP3715151:16NDND
AP8515181:32NDND
Control IgG25M01000<1:800
L32700≤1:800
  • a Neutralization of SHIV162P4by b12 (IC90) was achieved at a b12 concentration of 2 μg/ml. ND, not done.

  • b All neutralization assays were performed with SHIV162P4 challenge virus in PHA-activated rhesus PBMC and determination of p27 antigen by ELISA.